Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

Published:2024-08 Issue: Volume: Page:
ISSN:0365-0596
Container-title:Anais Brasileiros de Dermatologia
language:en
Short-container-title:Anais Brasileiros de Dermatologia

Author:

Mansilla-Polo Miguel^ORCID,Sahuquillo-Torralba Antonio^ORCID,Pujol-Marco Conrad^ORCID,Bargues-Navarro Guillermo^ORCID,Botella-Estrada Rafael^ORCID

Publisher

Elsevier BV

Reference9 articles.

1. Psoriasis and treatment: past, present and future aspects;Reid;Acta Derm Venereol,2020

2. Anti-IL 23 biologics for the treatment of plaque psoriasis;Vu;Expert Opin Biol Ther,2022

3. Selective Il-23 inhibitors: the new kids on the block in the treatment of psoriasis;Torres;Actas Dermosifiliogr (Engl Ed),2018

4. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis;Chiricozzi;Eur J Dermatol,2021

5. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence;Ruggiero;Clin Cosmet Investig Dermatol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP